Role of Erythropoietin in Renal Anemia Therapy

Xing, Xuekun; Zhang, Wenbo; Sun, Huishan

doi:10.4314/tjpr.v15i5.26

Cited by 4 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, the prevention and treatment of anemia is a key factor in improving survival for CKD patients. At present, there are many methods to treat renal anemia, mainly the use of ESA [5] , iron supplementation, and, to a lesser extent, blood transfusion [6] .…”

Section: Discussionmentioning

confidence: 99%

A Cross-Sectional Study on The Prevalence of Anemia in Maintenance Hemodialysis and Peritoneal Dialysis Patients and Its Related Factors

Huang

2024

JCNR

View full text Add to dashboard Cite

Objective: To study the prevalence of anemia, the proportion of hemoglobin (Hb) levels, the treatment methods, and the influencing factors of Hb levels in maintenance hemodialysis (MHD) and peritoneal dialysis patients. Methods: In this study, 602 patients with maintenance hemodialysis and continuous ambulatory peritoneal dialysis were enrolled from December 2020 to December 2022 in our hospital, and their medical records were collected and summarized. The main contents included the patient’s gender, age, primary disease, dialysis duration, dialysis method, the use of erythropoietic stimulating agents (ESA), intravenous iron, and laboratory tests. A Hb index exceeding 110 g/L was set as the standard for the prevalence of anemia. Results: The rate of anemia in patients undergoing blood purification was 83%. The proportion of ESA use was 84.1%, and the proportion of iron use was 76.7%, of which the proportion of intravenous iron used was 17.0%, and the proportion of folic acid used was 28.3%. Conclusion: The incidence of anemia in MHD patients was relatively high, with a low proportion of patients reaching the standard Hb levels. Risk factors include albumin (ALB) levels, iron storage, white blood cells, C-reactive protein, cholesterol, etc. Nutritional support, iron supplementation, and prevention of micro-inflammatory reactions can effectively promote the improvement of Hb indicators in dialysis patients to prevent anemia.

show abstract

Section: Discussionmentioning

confidence: 99%

A Cross-Sectional Study on The Prevalence of Anemia in Maintenance Hemodialysis and Peritoneal Dialysis Patients and Its Related Factors

Huang

2024

JCNR

View full text Add to dashboard Cite

show abstract

“…EPO menstimulasi proliferasi dan diferensiasi sel di sumsum tulang, dan meningkatkan pembentukan sel darah merah. Kerusakan pada tubulus ginjal atau jaringan glomerular dapat menghambat produksi EPO (Xing, Zhang and Sun, 2016). Penyebab lain anemia pada penyakit ginjal kronik adalah defisiensi besi, inflamasi, umur eritrosit yang memendek, obat-obatan, factor tumor, penghambatan eritropoiesis oleh ureum (uremic inhibitors of erythropoiesis) dan hiperparatiroid sekunder (Indonesia, 2011;Babitt and Lin, 2012;Akizawa et al, 2018).…”

Section: Eritropoietin (Epo) Merupakan Glikoprotein Yang Disekresi Se...unclassified

Risk Factor for Erythropoietin Resistance in Hemodialysis Patient : Literature Review

Putri

Sholikhah

Sukirto

2020

ADMJ

View full text Add to dashboard Cite

Anaemia become the complication of chronic kidney disease (CKD) which was caused by decreasing of erythropoietin. Erythropoietin stimulating agent (ESA) therapy is one of therapy to overcome the problem, but until 34% of patients have lack of response to ESA treatment. Anaemia in CKD related to the worsen of the diseases, quality of life, and mortality of patients. Decreasing of the response to erythropoietin need to be evaluated to correct anaemic condition. This review is aim to explain the risk factor for erythropoietin resistance. The literature for this review was collected through PUBMED and google scholar. Erythropoietin is glycoprotein secreted 90% by interstitial cells of kidney and 10% by liver cells. The functions of erythropoietin are stimulate the proliferation and cells differentiation in bone marrow, and enhance erythropoiesis. Renal damage can inhibit the secretion of erythropoietin. In patients with ESA treatment, risk factors for resistance are iron deficiency, inadequate haemodialysis, inflammation, hyperparathyroid, nutrition disturbance, antibody mediated Pure Red Cell Aplastic (PRCA). The risk factor can be influenced by genetic variation. Conclusion of this review, there are several factor that influence the response of erythropoietin in hemodialisa patients. Hence, study related anaemia in CKD need further study to optimalize the treatment.

show abstract

“…Erythropoietin (EPO) is a glycoprotein growth hormone with a molecular weight of 34 kDa which stimulates the growth of erythroid progenitor cells (4). It is primarily produced in kidneys (4). It is released from the kidneys as a response to hypoxia and stimulates the hematopoietic system.…”

Section: Introductionmentioning

confidence: 99%

Effects of erythropoietin on bacterial translocation in a rat model of experimental colitis

et al. 2019

View full text Add to dashboard Cite

Objective: In this experimental study, it was aimed to assess the effects of erythropoietin (EPO) on bacterial translocation in a rat model of colitis. Material and Methods: The rats were randomly assigned into control, colitis and EPO-treated groups (n= 8 in each group). Saline solution (NS) was administered to control rats via rectal route. A trinitrobenzene sulfonic acid and ethanol mixture (TNBS-E) was used to induce colitis in the experiment groups. No treatment was administered to colitis group after induction. Starting at one day after induction of colitis with TNBS-E, EPO (1000 IU/kg) was administered subcutaneously for three days to the rats in the EPO-treated group. Colonic inflammation was assessed by gross and microscopic examination on day five. Blood samples were obtained to evaluate bacterial translocation while hepatic, mesenteric tissue samples and mesenteric lymph node (MLN) samples were collected for tissue culture. Tissue myeloperoxidase (MPO) levels, and tumor necrosis factor alpha (TNF-α) and endotoxin levels in the sera were studied. Results: Significant gross and microscopic differences were found in the comparison between colitis and EPO-treated groups (p< 0.05). MPO level was significantly lower when compared to the colitis group (p< 0.05). Serum TNF-α and plasma endotoxin levels were significantly lower in the EPO-treated group than the colitis group (p< 0.05). Bacterial translocation was lower in the liver, spleen, MLNs and systemic blood in the EPO-treated group when compared to the colitis group (p< 0.05). Conclusion: In TNBS-E-induced rat model of colitis, EPO significantly decreased inflammation and bacterial translocation based on histopathological, biochemical and microbiological parameters.

show abstract

Role of Erythropoietin in Renal Anemia Therapy

Cited by 4 publications

References 32 publications

A Cross-Sectional Study on The Prevalence of Anemia in Maintenance Hemodialysis and Peritoneal Dialysis Patients and Its Related Factors

A Cross-Sectional Study on The Prevalence of Anemia in Maintenance Hemodialysis and Peritoneal Dialysis Patients and Its Related Factors

Risk Factor for Erythropoietin Resistance in Hemodialysis Patient : Literature Review

Effects of erythropoietin on bacterial translocation in a rat model of experimental colitis

Contact Info

Product

Resources

About